Aims: To investigate the effects of blood glucose control with antihyperglycaemic agents with minimal hypoglycaemia risk on cardiovascular outcomes in patients with type 2 diabetes (T2D).
29 million people in the United States and 420 million people worldwide have T2D, with a projected global prevalence of 642 million by 2040. 2, 3 Conventional T2D drugs in randomized controlled trials (RCTs), in contrast with the benefits on microvascular outcomes, have failed to show consistent beneficial effects on major adverse cardiovascular events (MACE). [4] [5] [6] [7] [8] [9] [10] [11] The inconsistency of evidence has led to the American Heart Association, the American College of Cardiology, and the American Diabetes Association providing a conservative class IIb recommendation with level of evidence A for the benefit of glycaemic control on cardiovascular disease. 12 Due to concerns regarding increased adverse CV events incurred by new diabetic drugs, 13 the US Food and Drug Administration and European Medicines Agency mandated that new diabetic therapies had to demonstrate CV safety in prospective, randomized controlled outcome trials. Although designed to address the safety issue, results from recent cardiovascular outcomes trials (CVOTs) have confirmed CV safety, as well as reduced CV and all-cause mortality in some studies. [14] [15] [16] Recently, it was shown that hypoglycaemia is associated with an increased risk of CV events, all-cause hospitalization, and all-cause mortality in a dose-response manner. 17, 18 Another cohort study has also confirmed this positive relationship. 19 Given that new T2D drugs are less prone to hypoglycaemia, their benefit-harm profiles on cardiovascular outcomes might be considerably different from those of conventional antihyperglycaemic agents. Moreover, a previous metaanalysis suggested that there were no significant differences in the associations between available classes of glucose-lowering drugs and the risk of cardiovascular or all-cause mortalities. 20 The metaregression analysis in this study did not evaluate the effect of blood sugar reduction on cardiovascular mortality. It was therefore hypothesized that the relative risk of MACE associated with the use of new T2D drugs is proportional to the reduction of blood glucose, estimated with haemoglobin A1c concentration (HbA1c).
To test this hypothesis, a meta-analysis and meta-regression analysis were conducted to systematically synthesize and investigate the relationship between HbA1c reduction and the outcomes of stroke, coronary heart disease (CHD), hospitalization for heart failure (HF), cardiovascular death, all-cause mortality and any major adverse CV events in the large endpoint-adjudicated RCTs for new T2D drugs with minimal hypoglycaemia risk.
| MATERIALS AND METHODS
The pre-specified protocol for this review was registered with PROS-PERO (number CRD42017071367) and the study report adhered to the PRISMA statement 21 recommended by the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network (Table S1 ). 
|

| Study selection
The inclusion criteria for eligible studies were: (1) RCTs comparing the effects of using intensive glucose-lowering drugs with a minimal hypoglycaemia hazard versus placebo or standard care, or comparison of one type of antihyperglycaemic agent with another type in patients with T2D, (2) those reporting major adverse cardiovascular events as the primary outcome and adjudicated by an independent committee, (3) those enrolling a total number of patients >1000 22 to avoid overestimation of the effect sizes from small trials 23 , and (4) those with a follow-up of more than 1 year. Trials using mainly insulin, sulfonylureas (SUs) or glinides in blood glucose management were excluded, as were trials investigating antidiabetic drugs withdrawn from the market.
Two researchers (C.-J. H. and W.-T. W.) performed the study selection procedure, and the selected studies were checked by a third researcher (H.-M. C.) for accuracy.
| Data extraction and quality assessment
Relevant data extracted from each eligible trial were collected in a spreadsheet containing information regarding study and participant characteristics, baseline and achieved HbA1c levels, mean difference in HbA1c between intervention and control groups, the antidiabetic regimens used, and outcome events. The methodological quality of the included trials was judged using the Cochrane Collaboration's tool for assessing the risk of bias 24 and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for rating the quality of evidence. 25 Two researchers (W.-T. W. and C.-J. H.)
independently performed the data extraction and quality appraisal, and any discrepancies were resolved through discussion with a third researcher (H.-M. C.).
| Outcomes
The primary outcome of interest was major adverse cardiovascular events (MACE), a composite endpoint which consisted of death from CV causes, non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes were myocardial infarction, stroke, death from CV causes, death from any cause, and hospitalization for heart failure according to the definition of each study. Safety outcomes including hypoglycaemia (any type of event) and severe hypoglycaemia (requiring third-party assistance) were also evaluated. Although patients on placebo may still receive conventional antidiabetic agents, taking into consideration the other balanced baseline characteristics, the relative effects between treatment and control arms on CV outcomes were mainly rendered by the effects of the testing strategies.
| Data synthesis and analysis
In this meta-analysis, aggregated data were used and a quantitative synthesis of the findings from the included studies was performed.
Because all adverse outcomes were binary indicators, the relative risk 
| RESULTS
Of the 4443 articles initially identified, 69 were further reviewed in full-text versions for assessing eligibility. Ten studies met the inclusion criteria and were chosen for this analysis ( Figure S1 ). 
| Study characteristics and quality assessment
| Achieved HbA1c difference and risk of adverse events
Univariable meta-regression analyses showed that the absolute risk reduction for MACE (P = 0.0005) and stroke (P = 0.0044) was proportional to the reduction in achieved HbA1c. With an increment of 1% in achieved HbA1c difference, the magnitude of risk reduction increased 4.43% for MACE (95% CI, 1.92%-6.94%) and 1.92% for stroke (95% CI, 0.60%-3.23%) ( Figure 1A and Figure S5 ). Similarly, a larger reduction in achieved HbA1c was significantly associated with a lower relative risk of MACE (P = 0.0008) and stroke (P = 0.0092) ( Figure 1B and Figure S6 ). Lowering HbA1c by 1% conferred a significant risk reduction of 30% (95% CI, 17%-40%) for MACE and 40%
(95% CI, 15%-57%) for stroke. By contrast, using conventional antihyperglycaemic agents, the results of meta-regression analysis ( Figures 1C and D) failed to demonstrate a significant relationship between achieved HbA1c difference and MACE risk (P > 0.74).
Further multiple meta-regression analyses were performed for MACE and stroke. The trend relationships from the estimates of absolute or relative effect of intervention were found in MACE after adjusting for possible confounders including age, sex, baseline HbA1c, duration of follow-up, difference in achieved SBP, difference in achieved body weight, or risk difference in hypoglycaemia (P < 0.05 for all models) ( Table 2 and Table S3 ).
| Effects of antihyperglycaemic treatment on major adverse cardiovascular events
When the effectiveness of different extents of lowering HbA1c was evaluated (Figure 2) , there was significant heterogeneity in the treatment effects across strata (P = 0.008; I 2 = 79.4%), with greater risk reductions in trials with a ≥ 0.5% difference in achieved HbA1c (relative risk reduction [RRR], 13%; 95% CI, 6%-20%; P = 0.0008) than in trials with a 0.3%-0.5% difference (11%;
95% CI, 4%-17%; P = 0.002), but no benefits were found in trials with a < 0.3% difference in achieved HbA1c (0%; 95% CI, −7%- 6%; P = 0.90). Overall, antihyperglycaemic treatment significantly reduced the risk of MACE by 8% (95% CI, 3%-13%; P = 0.002) compared to placebo.
The efficacy of four classes of oral antidiabetic agents in the prevention of MACE in patients with T2D was also assessed. The results
showed that the effects of antihyperglycaemic treatment differed Univariable meta-regression for the relationship of achieved HbA1c difference between intervention and control groups with absolute risk reduction (A, C) and the natural logarithm of a relative risk (B, D) for MACE in patients with type 2 diabetes, according to trials using antidiabetic agents with minimal hypoglycaemia risk or conventional drugs as the option of intensive glycaemic management. The regression fit (solid line) and 95% CI (dashed line) are shown. The size of the circle represents the weighting of each trial and is inversely proportional to the standard error of the effect estimate. Beta coefficient depicts a change in absolute or relative effect of antihyperglycaemic treatment for each 1% difference in achieved HbA1c between intervention and control groups between drug classes (P = 0.03; I 2 = 65.3%) ( Figure S7 ). Compared to placebo, GLP-1 receptor agonists (RRR, 9%; 95% CI, 0%-17%; P = 0.048), SGLT2 inhibitors (14%; 95% CI, 6%-22%; P = 0.002) and thiazolidinediones (17%; 95% CI, 3%-29%; P = 0.02) were significantly associated with a decreased risk of MACE. A significant treatment effect with DPP-4 inhibitors was not found.
Using the GRADE system, the overall quality of the body of evidence was high for MACE when comparing antidiabetic drugs to placebo for patients with T2D (Table S4) . Nine fewer MACE (from three to 14 fewer) could be prevented per 1000 patients with T2D receiving antidiabetic drugs compared to placebo.
| Antihyperglycaemic treatment and hypoglycaemia risk
The risk of hypoglycaemia had no linear relationship with achieved
HbA1c difference between treatment and control groups ( Figure S8A ).
Antihyperglycaemic treatment conferred a significantly higher risk for hypoglycaemia than placebo (RR, 1.09; 95% CI, 1.01-1.18; P = 0.03),
with the excess risk contributed by the use of DPP-4 inhibitors or thiazolidinediones ( Figure S9 ). No increased risk for severe hypoglycaemia with antihyperglycaemic therapy was detected ( Figures S8B and S10 ).
The quality of evidence was moderate for hypoglycaemia and low for severe hypoglycaemia (Table S4) , and no publication bias was found (Egger's test P = 0.1583 for hypoglycaemia and 0.6741 for severe hypoglycaemia; data not shown).
| DISCUSSION
The present meta-analysis and meta-regression analysis of the CVOTs During median treatment of 2.6 years, reduction of HbA1c concentration by 1% resulted in significant reduction in the risk of MACE by 30%. This positive correlation was consistent with the result of a previous meta-regression analysis. 32 Similarly, in trials using conventional antihyperglycaemic agents, there has been no significant association between CV events and HbA1c reduction. The information obtained in the current study will be useful for clinicians when selecting the optimal antihyperglycaemic agents to avoid or reduce the huge health burden resulting from the high MACE rate in patients with T2D.
These results were consistent with the subgroup analysis (Figure 2 ), whereby the higher HbA1c reduction between the treatment and control groups was associated with a larger risk reduction in MACE, with the same result achieved in subgroup analysis by different categories of antihyperglycaemic agents. With different benefitharm profiles to traditional medication, new antihyperglycaemic agents, similar to antihypertensive 33 and anti-hypercholesterolemia drugs, 34 can bring about a predictable risk reduction in MACE, which is proportional to the reduction of these risk factors. Nevertheless, we cannot exclude the possibility that the benefits observed with GLP-1 receptor agonists, SGLT2 inhibitors and thiazolidinediones are at least partly due to the extra-glycaemic actions of these drugs. For example, the SGLT2 inhibitor, empagliflozin, markedly and rapidly reduced CV mortality and heart failure hospitalization, 14 which may be related to haemodynamic or metabolic-associated mechanisms. The GLP-1 receptor agonists, liraglutide 16 and semaglutide, 15 reduced CV death and MACE with beneficial effects appearing more slowly, and did not influence heart failure risks, suggesting possible alternative mechanisms of benefit. 35 In currently available trials, the control group is not simply represented by placebo: study protocols recommend the adjustment of concurrent therapies for reaching an optimal glucose control in all patients; as a result, T2D patients in placebo groups are more often treated with insulin and SUs than those on active treatment. As shown in a previous meta-analysis of 115 RCTs, the use of SUs is associated with increased mortality and a higher risk of stroke. 36 Moreover, SUs did increase the risk of hypoglycaemic episodes when compared with DPP-4 inhibitors 37, 38 or metformin, regardless of the individual sulfonylurea. 39 Therefore, it is possible that part of the differences in outcome is determined by the detrimental effects of conventional therapies on some cardiovascular outcomes.
During the UK Prospective Diabetes Study, 40 risk reductions for myocardial infarction and death from any cause emerged in the 10 years of follow-up. However, the ADVANCE 7 and ACCORD 41 trials suggested that significant differences in HbA1c concentration might not confer benefits to macrovascular events, and may even cause an excess risk of all-cause mortality, possibly associated with the higher drug-related adverse events of the hypoglycaemia. A metaanalysis of data from 13 RCTs suggested intensive glucose-lowering treatment resulted in a 19% increase in all-cause mortality and a 43% increase in CV death. 42 By contrast, one meta-analysis using pooled data from ACCORD, ADVANCE and UKPDS showed an overall reduction in the risk of major CV events by 9%, and a 15% reduction in myocardial infarction. 6 Another meta-analysis from five RCTs of 33 040 participants provides reassurance about the effectiveness of intensive glycaemic control for cardiovascular risk reduction (17% reduction in events of non-fatal myocardial infarction and 15% reduction of coronary heart disease). 31 Possible explanations of such differing results may be (1) that treatment duration was shorter than necessary to reveal a clinical benefit, 40 thus event rates were lower than expected due to improved control of risk factors, (2) differences in glycaemic control between patients' groups were too small to show benefit, and (3) the prevalent side effects of hypoglycaemia, which may counteract the benefit from intensive glucose control with insulin and SUs. 17, 18 The last of these helps explain why the beneficial effects of glucose-lowering in previous diabetic trials using insulin and SUs only emerged after a longer follow-up duration. This could be because the risk associated with hypoglycaemia resulting from conventional antihyperglycaemic agents may dilute the protective effects of blood sugar control. Such dilution requires a longer follow-up duration and a larger event number to counterbalance it. Overall, these discrepancies indicate that the role of glucose control in patients with T2D who receive glycaemic therapy has only now been determined.
These findings are in agreement with the results of a systematic review which investigated the impact of incretin-based treatment including both GLP-1 agonists and DPP-4 inhibitors on all-cause mortality in patients with T2D. 43 Although no meta-regression analysis was conducted, by including a few large and several small RCTs as well as registry reports, results suggested a probable mortality benefit with GLP-1 agonists. 43 In addition to the risk conferred from hyperglycaemia, CV risk may also be modulated by various mechanisms including baseline characteristics such as duration since T2D diagnosis at baseline (≥10 years), the baseline HbA1c concentration, and the adverse side effects of T2D drugs. For example, in the ACCORD trial, HbA1c fell rapidly by around 1.5% within 6 months and the average HbA1c was less than 6% after 1 year in intensively treated individuals through the aggressive use of bolus insulin doses when necessary, and by them receiving a greater proportion of rosiglitazone at the end of follow-up compared with those receiving standard treatment (92% vs 58%). 41 The adverse effects of a 2.5 kg difference in weight gain and nearly double the number of severe hypoglycaemic episodes compared with standard treatment were recorded. More importantly, the metaregression analysis accounts for these potentially confounding effects, and still shows a significant linear relationship between HbA1c difference and the risk reduction in MACE.
Despite DPP-4 inhibitor being associated with a low risk of hypoglycaemia, 28 it failed to show a corresponding significant risk Effects of antihyperglycaemic treatment on MACE in patients with type 2 diabetes, stratified by achieved HbA1c difference between intervention and control groups. Mean HbA1c difference indicates the difference in achieved HbA1c between intervention and control groups. Diamonds denote the pooled estimate of relative risks and 95% CI reduction in MACE ( Figure S7) . As suggested by the meta-regression analysis in Figure 1 and subgroup analysis by the magnitude of HbA1c reduction in Figure 2 , the small benefit of DPP-4 inhibitor on MACE in these CV safety trials is probably related to its small amount of HbA1c differences.
Antidiabetic drugs with a low hypoglycaemic potential can increase the risk of hypoglycaemia when added to insulin or SUs. If hypoglycaemia is detrimental for the CV system, this could result in an underestimation of the potential benefits of the reduction of HbA1c.
In order to have a reliable assessment of the effects of the improvement of glycaemic control on CV events, a large trial is needed on the intensification of therapy, in which insulin and SUs are not allowed, or allowed only as rescue therapy.
| Study limitations
This study has several potential limitations. First, similar to other meta-analyses, the absence of primary data to analyze the effects of intensive glycaemic control within various patient subgroups by gender, prevalence of CV disease at baseline, comorbidity, duration of T2D, and the selective reporting of primary studies might confound the results. Second, these results should be interpreted carefully because of the significant heterogeneity with respect to the demographic characteristics of participants, duration of follow-up, and medication for intensive glucose control. Third, no evidence of superiority or harm of a specific glucose-lowering regimen can be provided without access to individual participant data. Finally, despite the comprehensive literature search, and by keeping the probability of bias to a minimum by developing a detailed protocol and using explicit criteria for study selection, data collection and data analysis, other eligible published or unpublished studies may have been excluded. However, similar to trends reported in previous meta-analyses, 6 due to robust methodology the results and conclusions would be unlikely to alter substantially, and therefore provide reliable recommendations for clinical practice.
In conclusion, compared with placebo, newer T2D agents with less hypoglycaemic hazard significantly reduced the risk of MACE.
The MACE reduction appears to be associated with HbA1c reduction in a linear relationship.
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